177LU-PNT2002 PSMA THERAPY vs Pluvicto

[Ollie1948]

It is my understanding this new drug presently under clinical trials is supposed to be a future alternative to Pluvicto... can anyone shed some light about this new drug and how it competes with Pluvicto? Thanks

[Tall_Allen]

Hopefully, it will be a more specific ligand=less toxicity. It is one of several in clinical trials.

[tango65]

The Lu 177 PNT 2002 is also known as LU 177 PSMA I&T and it was developed in Munich at Technical University of Munich.

oncidiumfoundation.org/mole...

This ligand is smaller than the ligand in Pluvicto. This could give to the I&T ligand a theoretically advantage in the penetration of the cancer cell.

It seems there is not a major difference in overall survival between the 2 ligands when treating patients with mCRPC.

pubmed.ncbi.nlm.nih.gov/352...

I had treatment with this ligand in 2016. It was effective.

[NotDFL in reply to tango65]

Copied from the paper:

the rate of clinically relevant toxicities was low for both compounds.

Median overall survival was 13 months for both agents.

[db1966 in reply to tango65]

hello tango65. I’m starting Pluvicto in January and maybe considering a cancellation and taking a December 22nd slot. Curious about the side effects and how you are doing these days.

[Ollie1948 in reply to db1966]

Presently I am on the Lu 177 PNT 2002 clinical trial and I got the first infusion two weeks ago. So far negligible side effects if any other of some fatigue and extra sleep during the first 8-10 days.

[db1966 in reply to Ollie1948]

thanks Ollie. Hope all goes well for you with the trial. I’m getting nervous about starting Pluvicto as I may take a cancellation and start December 22nd 😩😩

[tango65 in reply to db1966]

I had only 1 treatment because it made all the mets PSMA negative. No mayor negative effects. Some fatigue for 24 hours and some edema which resolved in 24 hours.